EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
…, T Kvien, Z Li, X Mariette, I McInnes, E Mysler… - Annals of the …, 2017 - ard.bmj.com
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international Task …
Against Rheumatism (EULAR) RA management recommendations. A large international Task …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
…, Z Li, X Mariette, U Müller-Ladner, EF Mysler… - Annals of the …, 2020 - ard.bmj.com
Objectives To provide an update of the European League Against Rheumatism (EULAR)
rheumatoid arthritis (RA) management recommendations to account for the most recent …
rheumatoid arthritis (RA) management recommendations to account for the most recent …
Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs …
…, JD McKay, EL Nasonov, EF Mysler… - … : Official Journal of …, 2008 - Wiley Online Library
Objective To examine the efficacy and safety of the humanized anti–interleukin‐6 receptor
antibody tocilizumab combined with conventional disease‐modifying antirheumatic drugs (…
antibody tocilizumab combined with conventional disease‐modifying antirheumatic drugs (…
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis
…, D Isenberg, D Jayne, LS Li, E Mysler… - Journal of the …, 2009 - journals.lww.com
Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages
over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these …
over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these …
Etanercept for the treatment of rheumatoid arthritis
Etanercept was the first specific anticytokine therapy approved for the treatment of rheumatoid
arthritis (RA). Its clinical efficacy and safety has been demonstrated by several clinical …
arthritis (RA). Its clinical efficacy and safety has been demonstrated by several clinical …
[HTML][HTML] Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions …
…, JL Coindreau, T Dörner, E Mahgoub, E Mysler… - Current rheumatology …, 2017 - Springer
Purpose of Review Biosimilars of the reference biologic therapeutics infliximab, etanercept,
adalimumab, and rituximab are entering the market. Clinical and real-world data on the …
adalimumab, and rituximab are entering the market. Clinical and real-world data on the …
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer …
TJ Schnitzer, GR Burmester, E Mysler, MC Hochberg… - The Lancet, 2004 - thelancet.com
Background Cyclo-oxygenase 2 (COX2)-selective inhibitors should reduce ulcer complications
compared with non-selective non-steroidal anti-inflammatory drugs, but evidence is …
compared with non-selective non-steroidal anti-inflammatory drugs, but evidence is …
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes …
…, FWA Verheugt, TJ Schnitzer, GR Burmester, E Mysler… - The Lancet, 2004 - thelancet.com
Background The potential for cyclo-oxygenase 2 (COX2)-selective inhibitors to increase the
risk for myocardial infarction is controversial. The Therapeutic Arthritis Research and …
risk for myocardial infarction is controversial. The Therapeutic Arthritis Research and …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
…, K Lauper, Z Li, IB McInnes, EF Mysler… - Annals of the …, 2023 - ard.bmj.com
Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management
recommendations addressing the most recent developments in the field. Methods An international …
recommendations addressing the most recent developments in the field. Methods An international …
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a …
R Fleischmann, E Mysler, S Hall, AJ Kivitz, RJ Moots… - The Lancet, 2017 - thelancet.com
Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative …
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative …